DOCSLIB.ORG

COVID-19 Vaccine, an Update Pharmaceries Webinar March 23Rd, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccine, an Update Pharmaceries Webinar March 23Rd, 2021 COVID-19 Vaccine, an Update PharmaCEries webinar March 23rd, 2021 Fernanda Bonilla, MD Infectious Diseases Rania El-Lababidi, PharmD, EMHA, BCPS(AQ-ID), AAHIVP Senior Manager, Pharmacy Education and Training Co-Director, Antimicrobial Stewardship Program Fulvio Salvo, MD Allergy and Immunology Learning Objectives • Recognize the immunologic basis for SARS-CoV-2 vaccination and the importance of neutralizing antibodies associated with protection from infection • Define the phases of vaccine development and the different platforms used to develop SARS-CoV-2 vaccines • Discuss the immunogenicity and safety data for the different vaccine candidates Smallpox Control of mortality, morbidity and complications Eradication Elimination Mitigation of disease Sanitation severity Immunization Prevention of infection Protection of the Prevention unvaccinated of related population diseases Societal and cancer benefits Andrea et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bulletin of the World Health Organization 2008 Sanitation Immunization Variolation • Early 18th century - Smallpox or Variola inoculation Vaccination • 1796 Edward Jenner – Cowpox or Variola vaccinia inoculation from milkmaids Value of Immunization • Annual prevention of 6 million deaths worldwide • Global eradication of smallpox • Elimination of polio by wild viruses in the US Ehreth J. The global value of vaccination. Vaccine. 2003 Adverse Effects MMR Tetanus toxoid • Onset 10 d • Encephalitis in 1 in 2 million • Brachial neuritis 1 month after • Causal role not established • 1 per 100K recipients Meningococcal vaccine Yellow fever • Anaphylaxis 1 in 500K doses • Vaccine-associated viscerotropic • GBS 1.25 in 1 million doses disease in 1 in 400K doses Immune response to COVID-19 A Complex Reality Immune Response to SARS-CoV-2 • Role of innate immunity, cellular adaptive immunity, and antibodies • Duration of natural immunity • Pre-existing immunity to other CoV • Risks related to partial immunity • Vaccine design rationale Immune response to a viral infection Infection can be stopped here if neutralizing Ab are present Prodromal Phase SYMPTOMS Recovery Innate Immune Response Adaptive Immune Response • Standard response to any infection • Tailored response to the infection • Macrophage and neutrophils • Starts usually after 6-8 days produce cytokines and chemokines to contrast the virus and activate • Involves 2 main cell types with the immune system several subtypes: • B-cells • Antibodies can efficiently stop the • T-cells (CD4 & CD8) infection Adapted from WHO Innate Immunity in COVID-19 • Port of entry is mainly through the mucosal surfaces of the respiratory tract • In early phase of infection SARS-CoV-2 suppresses activation of innate immune system by inhibiting IFN type I and III response. Innate Immunity • Port of entry is mainly through the mucosal surfaces of the respiratory tract • In early phase of infection SARS-CoV-2 suppresses activation of innate immune system by inhibiting IFN type I and III response. • Delayed activation of the immune system may explain the prolonged incubation period and increase the viral replication • Late-onset hyperinflammatory response is probably driven by activated proinflammatory macrophage and neutrophils T-cell mediated immunity • Emerging evidences support a central role for T-cell mediated immune response to SARS-CoV-2. • 100% of convalescent patients has S protein-specific CD4 T- cell and 70% of CD8. Other antigens also induce specific T cell response (e.g. N and M proteins). • Tissue resident memory T-cells may be particularly important for disease protection • Priming of the immune response towards Th1 or Th2 may be important for disease severity and outcome T-cell mediate immunity: for how long? • 23/23 patients recovered from SARS-CoV-1 infection still had T-cells reactive to SARS-CoV- 1 N protein after 17 years from infection • These T-cells also reacted to SARS-CoV-2 Le Bert, Nature 2020 SARS-CoV-2 structure and antibodies Antibodies • SARS-CoV-2-specific IgM, IgG and IgA are detectable in patients’ serum starting from 1-2 weeks after infection. • Antibody levels correlate with magnitude of T-cell response • Higher levels are detected in patients with severe disease • Antibodies are produced against multiple epitopes • Antibody titers tend to decrease over time but specific epitopes and severity of the disease may account for the significant variation in duration of detectable Abs IgG anti-S IgG anti-N Lumley, Clin Inf Dis 2021 Neutralizing Antibodies Spike • High affinity antibodies directed against the S1-RBD are able to neutralize the virus • Other epitopes may also have protective effects: antibodies against S2 domain may block membrane fusion. • Treatment of older patients with ACEr2 mild COVID-19 with high-titer convalescent plasma can decrease progression to more severe forms of disease. Spike Protein S1 RBD S2 Do we have natural immunity against SARS- CoV-2? • Other 4 coronaviruses are known to infect humans (besides SARS-CoV-1 and MERS-CoV) and cause approx. 15% of common cold cases • Cross-reactive antibodies and T-cells between other coronaviruses and SARS-CoV-2 are present, but are usually directed against more conserved epitopes (N protein or other non structural proteins, but also to S2 domain) • While antibody titers decline rapidly, memory T-cell may persist for much longer time Possible effect of cross-reactive T-cell on SARS-CoV-2 replication and infection Model I: Central Memory T-Cell Infection less severe at individual level Possibly enhanced transmission due to high viral replication Model II: Follicular Th-Cell More efficient ab-induction, less symptoms less viral load. Mild/moderate reduction of transmission Model III: Tissue resident T-Cell Quicker response, symptoms significantly reduced Transmission reduced with lower viral load. Lipsitch, Nat Rev Immunol 2020 Can inefficient immune response be harmful? Antibody-dependent Enhancement of Infection or Inflammation • ADE of infection is a well-known phenomenon in other viral infection (e.g. Dengue) • Animal models showed potential for ADE also in CoV infections (mice) • Low titer non-neutralizing antibodies are at higher risk of inducing ADE What does the immunologist want from a good vaccine? To be able to induce predictable antibody response to relevant epitopes (neutralizing antibodies) To induce a T-cell response which is durable and beneficial (Th1 and not Th2) To provide a protection against the disease and its transmission To be safe and avoid vaccine-associated damage Immunological properties of main COVID- 19 vaccine candidate platforms Jeyanathan, Nat Rev Immunol 2020 Immunological properties of main COVID-19 vaccine candidate platforms Jeyanathan, Nat Rev Immunol 2020 Immunological properties of main COVID-19 vaccine candidate platforms Jeyanathan, Nat Rev Immunol 2020 Immunological properties of main COVID-19 vaccine candidate platforms Jeyanathan, Nat Rev Immunol 2020 Vaccine Development SARS-CoV-2 vaccines in development, Krammer F, Nature 2020 Phases of clinical trials Immunogenicity Safety Phases of clinical trials Optimal vaccine schedule Immunogenicity Safety Phases of clinical trials Efficacy Safety Immune response Optimal Vaccine schedule Vaccine Development SARS-CoV-2 vaccines in development, Krammer F, Nature 2020 Emergency Use Authorization Vaccine platforms Spike Protein Instructions SARS-CoV-2 vaccines in development, Krammer F, Nature 2020 mRNA Vaccines Vaccines that deliver a gene transcript into our cells to provoke an immune response • Snippets of viral mRNA: instruction for making proteins • mRNA packed into a lipid envelop • mRNA inside the cytoplasm interacts with a ribosome → starts making spike proteins • S proteins elicit an immune response Vaccine platforms Spike Protein Instructions SARS-CoV-2 vaccines in development, Krammer F, Nature 2020 174 63 8 Preclinical Clinical Development vaccines in use BioNtech/Pfizer Moderna Oxford/AstaZeneca Sinovac/Instituto Butuntan Wuhan Institute/Sinopharm Beijing Institue/Sinopharm Gamaleya Reasearch Institute CanSino Biologics Janssen Pharma Novavax Candidates in clinical phase https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines Factors related to vaccines platforms • Effectiveness • Speed of development • Scalability • Complexity of distribution: - Storage requirements - >1 dose https://emedicine.medscape.com/article/2500139 Inactivated Recombinant/ mRNA vaccines Adenovirus Vector Vaccine Adjuvant Product BBIBP-CorV mRNA BNT162b2 ChAdOx1/ AD26.CoV2 rAd26-S NVX-CoV2373 1273 AZD1222 .S and rAd5- S Company Sinopharm Moderna/ BioNTech/ Oxford/ J&J Gemalaya Novavax NIAID Pfizer AstraZeneca Research Institute Series 0, 21 days 0, 28 days 0, 21 days 0, 28 days 1-dose 0, 21 days 0, 21 days Ages > 18 years > 18 years 12-85 > 18 years > 18 years > 18 years 18-84 years Studied years* Phase of Phase III Phase III Phase III Phase III Phase III Phase III Phase III Development Doses per NR 10 5 10 5 NR 10 vial ○ Storage 2 – 8○C -20○C -70-20 + 10C ○forC 2 -20○C or Fridge -20○C Fridge weeks Fridge Stability NR Fridge: Fridge: 5d NR Fridge: 3 NR NR 30d RT: 6 hours mo RT: 6 RT: 6 h hours Inactivated Recombinant/ mRNA vaccines Adenovirus Vector Vaccine Adjuvant Product BBIBP-CorV mRNA 1273 BNT162b2 ChAdOx1/ AD26.CoV2.S rAd26-S NVX-CoV2373 AZD1222 and rAd5-S Company Sinopharm Moderna/ BioNTech/ Oxford/ J&J Gemalaya Novavax NIAID Pfizer AstraZeneca Research Institute Series 0, 21 days 0, 28 days 0, 21 days 0, 28
Load more

Recommended publications
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Immunizations
    Medicine Summer 2015 | Volume 14, Number 2 encephalitis tetanus RUBELLA MUMPS meningococus pertussis ENCEPHALITIS MEASLES PERTUSSIS ROTAVIRUS meningococus MUMPS meningococus MEASLES tuberculosis RUBELLA diphtheria CHICKENPOX meningococus CHICKENPOX pneumococus meningococus rotavirus ENCEPHALITIS PNEUMOCOCUS FEVER TETANUS DIPHTHERIA TETANUS hepatitismumps POLIO encephalitis hepatitis measles pneumococus POLIO DIPHTHERIA FEVER CHICKENPOX tuberculosisRUBELLA tuberculosis diphtheria DIPHTHERIA meningococusMUMPS pneumococus encephalitis ENCEPHALITIS polio TETANUS diphtheria pertussis polio hepatitisRUBELLA meningococus ENCEPHALITIS DIPHTHERIA MEASLES YELLOW RUBELLA TETANUS measles Immunizations MEASLESpolio meningococus PERTUSSIS MEASLES RUBELLA measles tetanus rubella YELLOW tuberculosisENCEPHALITIS pneumococus CHICKENPOX RUBELLA measles What physicians rubella pertussis PNEUMOCOCUS need to know encephalitis diphtheria MUMPS meningococustetanus pneumococus measles rubella tetanus measles rotavirus tetanus rubellaPOLIOmeningococus hepatitisHEPATITISFEVER PERTUSSIS RUBELLA FEVER hepatitis FEVER HEPATITIS chickenpox poliorubella encephalitisTETANUSpertussis rubella DIPHTHERIA rotavirus tuberculosis FEVERHEPATITIS POLIO yellow DIPHTHERIAYELLOW polio pneumococus YELLOW polio ENCEPHALITIS chickenpoxrubellaRUBELLA rotavirus ENCEPHALITIS pertussis ROTAVIRUS tetanus chickenpox hepatitisFEVER encephalitis ENCEPHALITIS POLIO rotavirus ROTAVIRUS DIPHTHERIA YELLOW pertussis PNEUMOCOCUS PERTUSSIS RUBELLA polio CHICKENPOX ROTAVIRUS pneumococus CHICKENPOXCHICKENPOX
    [Show full text]
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Meningococcal Vaccine Q & a for Healthcare Providers
    Meningococcal Vaccine Q & A for Healthcare Providers School meningococcal vaccine requirements Q1: When did the school meningococcal vaccine requirement take effect? A1: The meningococcal vaccine school requirement took effect on September 1, 2016. Q2: For what grades is meningococcal vaccine required? A2: Meningococcal vaccine is currently required for students entering or attending grades 7 through 12 in public, private and parochial New York State (NYS) schools. Q3: How many doses of meningococcal vaccine are required for grades 7 through 11? A3: One dose of meningococcal conjugate vaccine (MenACWY; sometimes abbreviated as MCV4; brand names Menactra or Menveo) is required for entry into grades 7 through 11. Q4: How many doses of meningococcal vaccine are required for grade 12? A4: A total of two doses of MenACWY vaccine, administered a minimum of 8 weeks apart, are required for entry into grade 12. The second dose must be administered no sooner than 16 years of age. However, if the first dose of MenACWY vaccine was received at 16 years of age or older, then a second dose will not be required. The NYS school immunization requirements allow for a grace period of up to 4 days before the 16th birthday for receipt of the dose. A dose of vaccine received 5 or more days before the 16th birthday will not meet the 12th grade meningococcal vaccine requirement. Q5: Is serogroup B meningococcal vaccine (MenB vaccine) required for grade 12? A5: No, MenB vaccine is not required for school attendance in NYS. In addition, doses of MenB vaccine will not meet the NYS MenACWY vaccine requirement.
    [Show full text]
  • Bill 2015 - Submission to the Senate Enquiry
    Committee Secretary Senate Standing Committees on Community Affairs PO Box 6100 Parliament House Canberra ACT 2600 12/10/2015 Dear Sir/Madam, Re: Social Services Legislation Amendment (No Jab No Pay) Bill 2015 - submission to the Senate enquiry My objections to the No Jab No Pay bill are outlined as follows: 1) 'Motivating' people financially targets the less well off only. The majority of previous conscious objectors are the well educated and higher earning class. It will force women out of the workforce and will not achieve a notable difference in vaccination rates or reduce disease. 2) The 'No Jab No Pay' policy is not targeting those who have forgotten to vaccinate but those who previously would have consciously objected to vaccinating. In a democratic society, it should not be possible to rule in favour of forcing medical procedures onto members of the public, particularly into the children of people who disagree fundamentally with the process. It would be a very sad day for Australia if medical procedures were forced on members of the public who genuinely believe it could harm them. To force not only unavoidably unsafe procedures but future unknown and untested medical procedures in indeterminable amounts on the children whose parents are not convinced of the safety or efficacy of such procedures, puts an end to freedom of choice, an end to human rights for Australians. 3) The science is NOT clear. The government and policy makers may have only been presented with one sided research but I reiterate, the science is NOT clear. Please see the attached list of peer reviewed research that offer information that may not otherwise have been presented to policy makers.
    [Show full text]
  • PROOF of IMMUNIZATION COMPLIANCE NORTHWESTERN STATE UNIVERSITY of LOUISIANA (Louisiana R.S
    PROOF OF IMMUNIZATION COMPLIANCE NORTHWESTERN STATE UNIVERSITY OF LOUISIANA (Louisiana R.S. 17:170.1 Schools of Higher Learning) SS Number: _____________________________________________ Date of Birth: Month _________________ Date ___________________ Year ________________ Name: __________________________________________________________________________________________________________________________________ Please Print (Last) (First) (Middle) Address: ________________________________________________________________________________________________________________________________ City: ______________________________________________________ State: ________________________________ ZIP Code: _____________________________ UNIVERSITY REQUIRED IMMUNIZATIONS: Physician or Other Health Care Provider Verification: (See other side) M-M-R (Measles, Mumps, Rubella-2 Doses Required) Tetanus Diphtheria (Td) Pertussis (Tdap) OR First dose: ___________________ Serologic Test: __________________ Td: ___________________ (Date) (Date within 10 years) (Date) OR Second dose: __________________ (Date) Result: _________________________ (Date) Tdap: ___________________ (Date within 10 years) OR □ Born before 1956 Meningitis Vaccine ACYW-135 (TWO doses of meningococcal conjugate vaccination separated by at least eight weeks.) First dose: ____________________________________ Vaccine Type: _______________________________________ (Date) Second dose: __________________________________ Vaccine Type: _______________________________________ (Date) UNIVERSITY REQUIRED IMMUNIZATIONS:
    [Show full text]
  • COVID-19 Vaccines: Summary of Current State-Of-Play Prepared Under Urgency 21 May 2020 – Updated 16 July 2020
    Office of the Prime Minister’s Chief Science Advisor Kaitohutohu Mātanga Pūtaiao Matua ki te Pirimia COVID-19 vaccines: Summary of current state-of-play Prepared under urgency 21 May 2020 – updated 16 July 2020 The COVID-19 pandemic has spurred a global effort to find a vaccine to protect people from SARS- CoV-2 infection. This summary highlights selected candidates, explains the different types of vaccines being investigated and outlines some of the potential issues and risks that may arise during the clinical testing process and beyond. Key points • There are at least 22 vaccine candidates registered in clinical (human) trials, out of a total of at least 194 in various stages of active development. • It is too early to choose a particular frontrunner as we lack safety and efficacy information for these candidates. • It is difficult to predict when a vaccine will be widely available. The fastest turnaround from exploratory research to vaccine approval was previously 4–5 years (ebolavirus vaccine), although it is likely that current efforts will break this record. • There are a number of challenges associated with accelerated vaccine development, including ensuring safety, proving efficacy in a rapidly changing pandemic landscape, and scaling up manufacture. • The vaccine that is licensed first will not necessarily confer full or long-lasting protection. 1 Contents Key points .................................................................................................................................. 1 1. Types of vaccines ...............................................................................................................
    [Show full text]
  • Recommended and Minimum Ages and Intervals Between Doses
    Appendix A Recommended and minimum ages and intervals between vaccine doses(a),(b),(c),(d) Vaccine and dose number Recommended age Minimum age Recommended interval Minimum interval for this dose for this dose to next dose to next dose DTaP-1(e) 2 months 6 weeks 8 weeks 4 weeks DTaP-2 4 months 10 weeks 8 weeks 4 weeks DTaP-3 6 months 14 weeks 6-12 months(f) 6 months(f) DTaP-4 15-18 months 15 months(f) 3 years 6 months DTaP-5(g) 4-6 years 4 years — — HepA-1(e) 12-23 months 12 months 6-18 months 6 months HepA-2 ≥18 months 18 months — — HepB-1(h) Birth Birth 4 weeks-4 months 4 weeks HepB-2 1-2 months 4 weeks 8 weeks-17 months 8 weeks HepB-3(i) 6-18 months 24 weeks — — Hib-1(j) 2 months 6 weeks 8 weeks 4 weeks Hib-2 4 months 10 weeks 8 weeks 4 weeks Hib-3(k) 6 months 14 weeks 6-9 months 8 weeks Hib-4 12-15 months 12 months — — HPV-1 (Two-Dose Series)(l) 11-12 years 9 years 6 months 5 months HPV-2 11-12 years (+6 months) 9 years +5 months(m) — — HPV-1(n) (Three-Dose 11-12 years 9 years 1-2 months 4 weeks Series) HPV-2 11-12 years (+1-2 9 years (+4 weeks) 4 months 12 weeks (n) months) HPV-3(n) 11-12 years (+6 months) 9 years (+5 months) — — Influenza, inactivated(o) ≥6 months 6 months(p) 4 weeks 4 weeks IPV-1(e) 2 months 6 weeks 8 weeks 4 weeks IPV-2 4 months 10 weeks 8 weeks-14 months 4 weeks IPV-3 6-18 months 14 weeks 3-5 years 6 months IPV-4(q) 4-6 years 4 years — — LAIV(o) 2-49 years 2 years 4 weeks 4 weeks MenACWY-1(r) 11-12 years 2 months(s) 4-5 years 8 weeks MenACWY-2 16 years 11 years (+ 8 weeks)(t) — — MenB-1 Healthy adolescents: 16
    [Show full text]
  • A POX at Your House Chickenpox Parties Are an Old-School Method to Expose Kids to the Disease, but Are They Safe Alternatives Natural, Lifelong Immunity
    A POX at Your House Chickenpox parties are an old-school method to expose kids to the disease, but are they safe alternatives natural, lifelong immunity. Web sites such as diyfather.com or to an effective vaccine? “Chickenpox is a normal child- mothering.com give tips on how to by Sarah McCoy hood illness and I would rather not host a pox party with as much gusto vaccinate against a relatively minor as a birthday bash. sickness that will give permanent im- Parents who choose to enlist their Chickenpox parties are meant to munity,” says Jessica DelBalzo, moth- children in such parties claim they’ve be unsanitary. Children swap whis- er of two children, ages 2 and 6, who done their homework, weighed the tles, cups, lollipops and are encour- is desperately seeking a chickenpox risks and benefi ts, and made a thought- aged to cough without covering their party in Flemington, N.J. ful choice. mouths. The goal is to ensure every- Statistics on such parties are dif- Still, many in the medical commu- one gets some quality time with the fi cult to fi nd, but according to a nity shake their heads at such ideas. guest of honor, the varicella zoster vi- study done by the American Acade- “If parents came into my offi ce and rus, which lives in airborne respirato- my of Pediatricians, the chickenpox said they were going to a chickenpox ry droplets and is highly contagious. vaccine is the second most refused party, I would tell them that they were Parents who are more afraid of by parents, behind only the mea- putting their child’s life in danger,” says exposing their children to vaccines sles, mumps and rubella.
    [Show full text]
  • Artículos Científicos
    Editor: NOEL GONZÁLEZ GOTERA Número 064 Diseño: Lic. Roberto Chávez y Liuder Machado. Semana 291212 - 040113 Foto: Lic. Belkis Romeu e Instituto Finlay La Habana, Cuba. ARTÍCULOS CIENTÍFICOS P ublicaciones incluidas en P ubMED durante el período comprendido entre el 29 de diciembre de 2012 y el 4 de enero de 2013. Total de artículos reuperados con “vaccin*” en título: 68 Vacunas meningococo (Neisseria meningitidis) 13. Up take of meningococcal va ccine in Arizona schoolchildren after implementation of school- entry immunization requirements. Simpson JE, Hills RA, Allwes D, Rasmussen L. Public Health Rep. 2013 Jan;128(1):37-45. PMID: 23277658 [PubMed - in process] Related citations 33. A cute Cerebellar Ataxia Following Meningococcal Group C Conjugate V accination. Cutroneo PM, Italiano D, Trifirò G, Tortorella G, Russo A, Isola S, Caputi AP, Spina E. J Child Neurol. 2012 Dec 28. [Epub ahead of print] PMID: 23275434 [PubMed - as supplied by publisher] Related citations 39. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer m embrane vesicle va ccine against serogroup B meningococcal disease. Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP. 1 Vaccine. 2012 Dec 27. doi:pii: S0264-410X(12)01815-4. 10.1016/j.vaccine.2012.12.031. [Epub ahead of print] PMID: 23273968 [PubMed - as supplied by publisher] Related citations 40. P riorities for research on meningocccal disease and the impact of serogroup A va ccination in the African meningitis belt. [No authors listed] Vaccine. 2012 Dec 27. doi:pii: S0264-410X(12)01820-8.
    [Show full text]
  • HPV and Adolescent Vaccine Toolkit: Clinician Guide Contents
    HPV and Adolescent Vaccine Toolkit: Clinician Guide CONTENTS I. 2018 IMMUNIZATION SCHEDULES & SCREENING RESOURCES Recommended & Catch-up Immunization Schedule (Birth-18 Years) Lists the ages or age range each vaccine is recommended. Schedules are updated annually. Please visit https://www.cdc.gov/vaccines/schedules/ for the most up-to-date schedules. Clinician FAQ: CDC Recommendations for HPV Vaccine 2-Dose Schedules Helps explain the new HPV vaccine recommendation for adolescents (2 doses recommended for adolescents starting the series before their 15th birthday; 3 doses recommended for adolescents starting the series after their 15th birthday) and provides tips for talking to parents about the change. HPV 2-Dose Decision Tree Follow the decision tree chart to determine whether your patient needs two or three doses of HPV vaccine. II. ADDRESSING VACCINE HESITANCY Talking to Parents About the HPV Vaccine A collection of questions parents may have surrounding the HPV vaccine and responses healthcare providers can use to address the concerns. Let’s Talk Vaccines: A Guide to Conversations About Immunizations Parents ask tough questions! Use this resource from Northwest Vax to provide a strong recommendation using the Ask. Acknowledge. Advise model. III. BEST PRACTICES AND STRATEGIES FOR IMPROVING IMMUNIZATION COVERAGE RATES Strategies for Improving Adolescent Immunization Coverage Rates Use the strategies in this AAP resource to help your practice improve adolescent immunization coverage rates among your patients. Documenting Parental Refusal to Have Their Children Vaccinated Provides tips from the AAP on ways to communicate with and educate parents who refuse immunizations. Includes a template for use by health care providers to document refusals.
    [Show full text]
  • 1 What Is the Efficacy of COVID-19 Vaccinations in Preventing Disease Transmission to the Non-Vaccinated?
    National Health Library and Knowledge Service | Evidence Team CURRENT AS AT 02 April 2021 Summary of Evidence: COVID-19 | Question 199 VERSION 1.0 The following information resources have been selected by the National Health Library and Knowledge Service Evidence Virtual Team in response to a question from the National Immunisation Advisory Committee (NIAC). The resources are listed in our estimated order of relevance to practicing healthcare professionals confronted with this scenario in an Irish context. In respect of the evolving global situation and rapidly changing evidence base, it is advised to use hyperlinked sources in this document to ensure that the information you are disseminating to the public or applying in clinical practice is the most current, valid and accurate. For further information on the methodology used in the compilation of this document including a complete list of sources consulted please see our National Health Library and Knowledge Service Summary of Evidence Protocol. QUESTION 199 What is the efficacy of COVID-19 vaccinations in preventing disease transmission to the non-vaccinated? Question 199 was prepared by the National Health Library and Knowledge Service in collaboration with the Research Subgroup of the National Immunisation Advisory Committee (NIAC). National Health Library and NIAC Knowledge Service | Evidence Team 1 National Health Library and Knowledge Service | Evidence Team CURRENT AS AT 02 April 2021 Summary of Evidence: COVID-19 | Question 199 VERSION 1.0 What is the efficacy of COVID-19 vaccinations in preventing disease transmission to the non-vaccinated? Main Points 1. Emerging evidence suggests that COVID-19 vaccines may also reduce asymptomatic infection, and potentially transmission.
    [Show full text]